Streetbeat News

Stock Prices

ALXO

ALX Oncology Holdings Inc. (NASDAQ:ALXO) released topline data from its Phase 2 ASPEN-06 clinical trial, showing that the combination of evorpacept with standard therapy improved response rates and duration in HER2-positive gastric/GEJ cancer patients. Despite positive results, ALXO stock fell 34.40% in premarket trading.

Portfolio Pulse from Vandana Singh

August 01, 2024 | 1:05 pm

UNTY

Unity Bancorp, Inc. (NASDAQ:UNTY) has announced a new share repurchase program, allowing the company to buy back up to 500,000 shares, or approximately 5% of its outstanding common stock. The repurchase will depend on various factors including market conditions and the company's financial performance.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 1:04 pm

RBLX

Roblox shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 1:03 pm

CWT

California Water Service Group (NYSE:CWT) reported Q2 2024 GAAP EPS of $0.70, beating the analyst estimate of $0.44 by 59.09%. However, sales of $244.30 million missed the estimate of $216.25 million, representing a 100% decrease from $194.04 million in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 1:01 pm

TMDX

Over the past three months, six analysts have shared their insights on TransMedics Gr (NASDAQ:TMDX), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased to $160.17, with a high estimate of $200.00 and a low estimate of $120.00. Analysts have raised their price targets in response to the company's strong financial performance, including a 133.07% revenue growth rate and a net margin of 12.59%.

Portfolio Pulse from Benzinga Insights

August 01, 2024 | 1:00 pm

ENTG

Analysts have provided mixed ratings for Entegris (NASDAQ:ENTG) in the latest quarter, with a majority being bullish. The average 12-month price target is $152.17, reflecting a slight increase from the previous target. Despite positive analyst sentiment, Entegris faces challenges in revenue growth, net margin, ROE, ROA, and debt management.

Portfolio Pulse from Benzinga Insights

August 01, 2024 | 1:00 pm

KKR

KKR (NYSE:KKR) received mixed analyst ratings over the last quarter, with a majority being bullish. The average 12-month price target increased to $125.38. KKR's financials show strong revenue growth but challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

August 01, 2024 | 1:00 pm

WRBY

Analysts have provided mixed reviews on Warby Parker (NYSE:WRBY) over the past quarter, with a range of opinions from bullish to bearish. The average 12-month price target has increased to $16.6, with a high of $19.00 and a low of $14.00. Recent evaluations show some analysts raising their price targets, reflecting a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Insights

August 01, 2024 | 1:00 pm

NBIX

Over the past three months, 7 analysts have shared their insights on Neurocrine Biosciences (NASDAQ:NBIX), with ratings ranging from bullish to bearish. The average 12-month price target is $168.29, with a high of $193.00 and a low of $152.00. Recent analyst actions include maintaining or raising ratings and price targets, reflecting positive sentiment. Neurocrine Biosciences has shown strong financial performance with a 22.57% revenue growth rate, a net margin of 8.42%, and a debt-to-equity ratio of 0.21.

Portfolio Pulse from Benzinga Insights

August 01, 2024 | 1:00 pm

FMC

FMC shares are trading higher following the release of their Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 12:58 pm